TETEC AG is a biotechnology company specializing in the development and manufacturing of cell-based medicinal products for the treatment of joint cartilage defects. The product portfolio includes the cartilage replacement therapies NOVOCART® 3D and NOVOCART® Inject, which are primarily distributed in the German market. Additionally, the company operates as a CDMO service provider for the pharmaceutical and biotechnology industry in the development and production of ATMPs. Following its sale by Aesculap AG in May 2024, the company is now part of the Canadian Octane BioTx Inc.
Die Entwicklung und die Herstellung sowie der Vertrieb von bioartifiziellem Gewebeersatz, zur Anwendung am Menschen. Die Gesellschaft ist berechtigt, sich an Unternehmen gleicher oder ähnlicher Art zu beteiligen.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Stuttgart Local Court, HRB 382393 (as of 21 August 2026)
| Name | Type | City |
|---|---|---|
| Robert Spiro | Vorstand | Emmaus |
Source: German Commercial Register (Handelsregister) Stuttgart Local Court, HRB 382393 (as of 21 August 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2023 | €10,751 | -€9,400 | €64,469,969 | 135 |
| 2022 | €10,751,384 | -€9,399,710 | €63,559,016 | 116 |
| 2021 | €11,575,000 | -€7,820,000 | €53,411,130 | 118 |
| 2020 | €10,919,339 | -€7,616,000 | €45,779,014 | 118 |
| 2019 | €10,176,272 | -€6,350,249 | €37,800,903 | 108 |
| 2018 | €9,474,251 | -€5,508,772 | €31,647,489 | 96 |
| 2017 | €8,463,517 | -€4,946,605 | €24,754,917 | 85 |
| 2016 | €8,228,051 | -€5,178,104 | €20,845,876 | 74 |
| 2015 | €7,653,329 | -€3,576,265 | €14,609,277 | 67 |
| 2014 | €5,810,090 | -€1,912,731 | €10,456,635 | 60 |
Sign in to download data
Source: German Commercial Register (Handelsregister) Stuttgart Local Court, HRB 382393 (as of 21 August 2026)
Luye Pharma AG
Miesbach · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
VDI/VDE Innovation + Technik GmbH
Berlin · Forschung und Entwicklung im Bereich Rechts-, Wirtschafts- und Sozialwissenschaften sowie im Bereich Sprach-, Kultur- und Kunstwissenschaften
SKZ - KFE gGmbH
Würzburg · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
| Cost type | Amount | Share |
|---|---|---|
| Selling Costs | €2,846 | 29.1% |
| Admin Costs | €2,060 | 21.1% |
| R&D Costs | €4,867 | 49.8% |
